Skip to main content
Keith McCrae, MD, Oncology, Cleveland, OH

KeithRMcCraeMD

Oncology Cleveland, OH

Hematologic Oncology

Director, Benign Hematology, Professor of Molecular Medicine, Cleveland Clinic

Dr. McCrae is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. McCrae's full profile

Already have an account?

  • Office

    11100 Euclid Ave
    Cleveland, OH 44106
    Phone+1 216-844-8500
    Fax+1 216-286-6341

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1985 - 1988
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 1982 - 1985
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1982
  • Dartmouth College
    Dartmouth CollegeBA, Summa Cum Laude, 1978

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 1999 - 2026
  • PA State Medical License
    PA State Medical License 1985 - 2002
  • NC State Medical License
    NC State Medical License 1982 - 1985
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Teacher of the Year Taussig Cancer Institute, Cleveland Clinic, 2013
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
  • American�s Top Doctors Castle Connoly, 2008
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura  
    Scully M, Cataland SR, Peyvandi F, Coppo P, Kn�bl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES ..., NEJM, 1/1/2019
  • Duration of anticoagulant therapy and VTE recurrence in patients with cancer  
    Khorana AA, McCrae KR, Milentijevic D, Fortier J, Nelson WW, Lalibert� F, Crivera C, Lefebvre P, Schein J., Supportive Care Cancer, 1/1/2019
  • Plasma Kallikrein Structure Reveals Apple Domain Disc Rotated Conformation Compared to Factor XI  
    Li C, Voos KM, Pathak M, Hall G, McCrae KR, Dreveny I, Li R, Emsley J., J. Thromb Haemost, 1/1/2019
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • The Burden of Disease and IMPACT of Immune Thrombocytopenia (ITP) on Patients: Results from an ITP Survey
    Keith R McCrae, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Characterization of Recombinant _2GPI Using Hydrogen-Deuterium Exchange and X-Ray Crystallography
    Keith R McCrae, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • High Molecular Weight Kininogen but Not Factor XII Deficiency Attenuates Acetaminophen-Induced Liver Injury in Mice
    Keith R McCrae, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Extracellular vesicles in cancer-associated thrombosis 
    Evans Center, Boston University School of Medicine, Boston MA - 1/1/2019
  • Pomalidomide in Hereditary Hemorrhagic Telangiectasia 
    San Juan, PRI - 1/1/2019
  • Special Symposium on the Basic Science of Hemostasis and Thrombosis 
    60th American Society of Hematology Annual Meeting - 12/3/2018
  • Join now to see all

Press Mentions

  • Cleveland Clinic Trial Shows Promise in Treating Bleeding Disorder
    Cleveland Clinic Trial Shows Promise in Treating Bleeding DisorderSeptember 20th, 2024
  • Cure HHT's Advocacy Effort, Support Helps NIH-Sponsored PATH Trial Become First Successful, Large-Scale Randomized Trial for HHT
    Cure HHT's Advocacy Effort, Support Helps NIH-Sponsored PATH Trial Become First Successful, Large-Scale Randomized Trial for HHTSeptember 19th, 2024
  • Cancer Drug Shows Promise for Treating Rare Bleeding Disorder
    Cancer Drug Shows Promise for Treating Rare Bleeding DisorderSeptember 18th, 2024
  • Join now to see all

Grant Support

  • Regulation Of Angiogenesis By KininogenNational Heart, Lung, And Blood Institute2010–2012
  • Regulation Of Angiogenesis By KininogenNational Heart, Lung, And Blood Institute2009–2010
  • Role Of Microparticles In The Anti-Phospholipid SyndromeNational Heart, Lung, And Blood Institute2006–2010
  • Hematology Training GrantNational Heart, Lung, And Blood Institute2004–2010
  • Transfusion Medicine/Hemostasis Clinical Research NetworkNational Heart, Lung, And Blood Institute2009
  • Tropomyosin In The Antiangiogenic Activity Of HKANational Heart, Lung, And Blood Institute2004–2007
  • Transfusion Medicine/Hemostasis Clinical Research Netwo*National Heart, Lung, And Blood Institute2002–2006
  • Anti Angiogenic Activity Of Cleaved HMW KininogenNational Cancer Institute2000–2004
  • Urokinase Receptor And Trophoblast InvasionNational Heart, Lung, And Blood Institute1997
  • Urokinase Receptor And Trophoblast InvasionNational Heart, Lung, And Blood Institute1994–1997
  • Role Of The Urokinase Receptor In Trophoblast InvasionNational Heart, Lung, And Blood Institute1993
  • Immune Trophoblast InjuryEunice Kennedy Shriver National Institute Of Child Health &Human Development1990–1992
  • Lupus Anticoagulant Induced Endothelial InjuryNational Heart, Lung, And Blood Institute1987–1988

Other Languages

  • Spanish